Update: Molecular radiotherapy: Survey and current status

Research output: Contribution to journalReview articlepeer-review


Molecular radiotherapy (MRT) is founded on the ability to identify or synthesize radionuclide carriers that recognize and bind to tumor-associated target molecules. Advances in our understanding of the molecular biology of cancer and other diseases have identified molecules and signaling pathways that we can now visualize, in vivo, for diagnosis, staging, and to identify optimal therapy and monitor patient response to therapy. These advances have also helped identify targets for MRT, making it possible to target radiation at the cellular and molecular level. MRT is typically administered systemically, intracavitary, or locoregional administration has also been examined. In contrast to chemotherapy, wherein all proliferating cells are affected, MRT delivers radiation to only those cells that express cancer markers.

Original languageEnglish (US)
Pages (from-to)531-540
Number of pages10
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number5
StatePublished - Oct 1 2008


  • Alpha-emitters
  • Lymphoma
  • MBIG
  • Radioimmunotherapy
  • Thyroid cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Update: Molecular radiotherapy: Survey and current status'. Together they form a unique fingerprint.

Cite this